Kiniksa inks li­cens­ing deal to take a Re­gen­eron castoff in­to Asian mar­kets

Af­ter dig­ging through Re­gen­eron’s trash bin, Kiniksa has man­aged to put to­geth­er a tiny run with the ag­ing drug Ar­c­a­lyst in re­cent years. Now, the com­pa­ny will look to break through in Asian mar­kets.

Huadong Med­i­cine will pay $22 mil­lion up­front and a po­ten­tial $640 mil­lion in down­stream mile­stones to ex­clu­sive­ly li­cense Kiniksa’s Ar­c­a­lyst, an IL-1α and IL-1β block­er, and Covid-19 an­ti­body can­di­date mavril­i­mum­ab in Asian mar­kets not in­clud­ing Japan, the part­ners said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.